Allogene Therapeutics (ALLO) Income from Continuing Operations (2019 - 2025)
Historic Income from Continuing Operations for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$41.3 million.
- Allogene Therapeutics' Income from Continuing Operations rose 3659.72% to -$41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.6 million, marking a year-over-year increase of 2365.49%. This contributed to the annual value of -$257.6 million for FY2024, which is 2129.01% up from last year.
- Per Allogene Therapeutics' latest filing, its Income from Continuing Operations stood at -$41.3 million for Q3 2025, which was up 3659.72% from -$50.9 million recorded in Q2 2025.
- In the past 5 years, Allogene Therapeutics' Income from Continuing Operations ranged from a high of $1.9 million in Q4 2021 and a low of -$97.0 million during Q1 2023
- In the last 5 years, Allogene Therapeutics' Income from Continuing Operations had a median value of -$66.4 million in 2024 and averaged -$64.5 million.
- As far as peak fluctuations go, Allogene Therapeutics' Income from Continuing Operations surged by 10276.07% in 2021, and later crashed by 504653.99% in 2022.
- Over the past 5 years, Allogene Therapeutics' Income from Continuing Operations (Quarter) stood at $1.9 million in 2021, then plummeted by 5046.54% to -$93.6 million in 2022, then grew by 15.8% to -$78.8 million in 2023, then grew by 27.02% to -$57.5 million in 2024, then rose by 28.2% to -$41.3 million in 2025.
- Its Income from Continuing Operations was -$41.3 million in Q3 2025, compared to -$50.9 million in Q2 2025 and -$59.8 million in Q1 2025.